| Dokumentenart: | Artikel | ||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Titel eines Journals oder einer Zeitschrift: | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | ||||||||||||||||||||||||||||||||||||||||||||||||
| Verlag: | AMER SOC CLINICAL ONCOLOGY | ||||||||||||||||||||||||||||||||||||||||||||||||
| Ort der Veröffentlichung: | ALEXANDRIA | ||||||||||||||||||||||||||||||||||||||||||||||||
| Band: | 24 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Nummer des Zeitschriftenheftes oder des Kapitels: | 31 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Seitenbereich: | S. 5060-9 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Datum: | 2006 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Institutionen: | Medizin > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) | ||||||||||||||||||||||||||||||||||||||||||||||||
| Identifikationsnummer: |
| ||||||||||||||||||||||||||||||||||||||||||||||||
| Klassifikation: |
| ||||||||||||||||||||||||||||||||||||||||||||||||
| Stichwörter / Keywords: | ALLOGENEIC BONE-MARROW; TUMOR-IMMUNOTHERAPY; VIVO PERSISTENCE; LYMPHOCYTES; REGRESSION; CLONES; CANCER; DONOR; INTERLEUKIN-2; SURVIVAL; | ||||||||||||||||||||||||||||||||||||||||||||||||
| Dewey-Dezimal-Klassifikation: | 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin | ||||||||||||||||||||||||||||||||||||||||||||||||
| Status: | Veröffentlicht | ||||||||||||||||||||||||||||||||||||||||||||||||
| Begutachtet: | Ja, diese Version wurde begutachtet | ||||||||||||||||||||||||||||||||||||||||||||||||
| An der Universität Regensburg entstanden: | Ja | ||||||||||||||||||||||||||||||||||||||||||||||||
| Dokumenten-ID: | 14492 |
Web of ScienceZusammenfassung
Purpose The adoptive transfer of in vitro generated tumor antigen-specific cytotoxic T lymphocytes (CTL) provides a promising approach to the immunotherapy of cancer. A phase I study was conducted to test the feasibility, safety, and survival of adoptively transferred Melan-A-specific CTL lines in melanoma patients. Patients and Methods Eleven HLA-A2(+) patients with metastatic melanoma received ...
Zusammenfassung
Purpose The adoptive transfer of in vitro generated tumor antigen-specific cytotoxic T lymphocytes (CTL) provides a promising approach to the immunotherapy of cancer. A phase I study was conducted to test the feasibility, safety, and survival of adoptively transferred Melan-A-specific CTL lines in melanoma patients. Patients and Methods Eleven HLA-A2(+) patients with metastatic melanoma received at least three intravenous infusions of Melan-A -specific CTL at 2-week intervals. CTL were generated by four rounds of in vitro stimulation of purified CD8(+) peripheral blood lymphocytes with autologous dendritic cells pulsed with an HLA-A2 binding Melan-A peptide. Each T-cell infusion was accompanied by a 6-day course of low-dose interleukin-2. Results A total of 52 T-cell infusions were administered, averaging 2.1 x 10(8) Melan-A -specific CTL per infusion. Clinical adverse effects were mild and consisted of chills and low-grade fever in seven of 11 patients. Clinical and immunologic responses revealed an antitumor response in three of 11 patients ( one complete regression, one partial regression, one mixed response), an elevated frequency of circulating Melan-A tetramer(+) T cells up to 2 weeks in all the patients with a maximal frequency of 2% of total CD8(+) T cells, an increase in eosinophils to up to 50% in seven of 11 patients, and a selective loss of Melan-A expression in lymph node metastases in two evaluated patients after T-cell transfer. Conclusion Our data indicate that the adoptive transfer of antigen-specific T cells in melanoma patients can induce clinical tumor-specific immune responses without major adverse effects.
Metadaten zuletzt geändert: 29 Sep 2021 07:37
Altmetric